Core Viewpoint - After a historic 10-day rally, the largest medical ETF in A-shares (512170) experienced a pullback, with the index dropping over 1% on July 31, 2023, and the medical sector also declining [1][4]. Market Performance - The medical ETF (512170) recorded a daily fluctuation of 2.67%, with a trading volume of 1.02 billion yuan, remaining at a relatively high level [1]. - In July, the medical ETF saw a cumulative increase of 11.48%, outperforming the Shanghai Composite Index (+3.74%) and the ChiNext Index (+8.14%) [2][4]. Sector Analysis - Major CXO stocks, including WuXi AppTec, experienced significant declines, with WuXi AppTec down 2.61% and a trading volume of 9.499 billion yuan, marking a near four-month high [4]. - Other medical device giants like Mindray Medical and Aier Eye Hospital also saw declines of over 2% [4]. Policy and Industry Outlook - There is a growing support from the government for innovative medical devices, as indicated by recent meetings held by the National Healthcare Security Administration [6]. - The policy shift aims to alleviate low-price competition in the industry and accelerate the development of high-end domestic medical devices [6]. - Public funds have increased their allocation to the medical sector, with the top ten A-share funds holding 11.51% in the medical sector, up 1.51% from the previous quarter [6]. Investment Opportunities - The medical ETF (512170) is highlighted as a potential investment opportunity, focusing on "medical devices + medical services" and is closely related to AI in healthcare [7]. - The first pharmaceutical ETF (562050) is also recommended, focusing on 50 leading pharmaceutical companies, emphasizing innovative drugs and high-barrier generic drugs [7].

Core Viewpoint - The A-share medical ETF (512170) experienced a correction after a historic 10-day rally, with a notable decline on July 31, 2025, where the ETF fell by 1.6% and lost its 5-day moving average [1][3]. Group 1: Market Performance - The medical ETF (512170) recorded a cumulative increase of 11.48% in July, outperforming the Shanghai Composite Index (+3.74%) and the ChiNext Index (+8.14%) [4]. - On July 31, 2025, the medical ETF showed increased volatility with a daily trading range of 2.67% and a trading volume of 1.02 billion yuan, indicating active market participation [1][3]. Group 2: Sector Adjustments - Major CXO stocks, including WuXi AppTec, saw significant declines, with WuXi AppTec dropping 2.61% and a trading volume reaching 9.499 billion yuan, marking a four-month high [3]. - Other medical giants like Mindray Medical and Aier Eye Hospital also experienced declines of over 2% [3]. Group 3: Policy and Future Outlook - Recent policy shifts indicate a growing support for innovative medical devices, with the National Healthcare Security Administration holding discussions on new pricing policies for innovative drugs and devices [6]. - The trend of "anti-involution" in the medical sector is expected to alleviate low-price competition, potentially accelerating the development of high-end domestic medical devices [6]. - Public funds are increasing their allocation to the medical sector, with the top ten A-share funds holding 11.51% in the medical sector, reflecting a 1.51% increase [6][7].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The pharmaceutical sector is experiencing a shift from price competition to quality and value competition due to the new procurement policies aimed at alleviating the low-price competition dilemma [2][11] - There is increasing policy support for innovative drugs and medical devices, which is expected to accelerate the development of high-end domestic medical devices [18] Summary by Sections Market Performance - The overall A-share market rose by 1.70%, with the biotechnology sector outperforming at a 1.90% increase [23] - The medical services sector led the gains with a 6.73% increase, while chemical pharmaceuticals saw a decline of 1.23% [23] Procurement Policy Changes - The 11th batch of centralized procurement emphasizes "anti-involution," allowing medical institutions to choose based on brand and requiring the lowest bidders to justify their pricing [17][15] - This policy aims to shift focus from aggressive price competition to quality and value, benefiting leading companies in the industry [15][17] Support for Innovation - Recent announcements from the National Medical Products Administration and the National Healthcare Security Administration indicate a commitment to support the innovation of high-end medical devices and drugs [18] - The average annual growth rate of healthcare spending on innovative drugs is projected at 40% from 2020 to 2024 [18] Company Earnings Forecasts and Ratings - Major companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform" with projected earnings growth [4] - Mindray Medical is expected to see a rise in net profit from 116.7 billion in 2024 to 161.9 billion by 2027, with a PE ratio decreasing from 24.1 to 17.4 over the same period [4] Recommended Stocks - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic healthcare infrastructure and product upgrades [33] - WuXi AppTec is noted for its comprehensive service capabilities in the new drug development sector, poised to benefit from the global outsourcing market [33] - Aier Eye Hospital is recognized for its rapid expansion in the eye care sector, supported by a strong brand and operational capabilities [33]